Pfizer is acquiring Metsera for up to $10 billion to enter the weight-loss drug market. Pfizer’s revenue has declined, but it aims to boost its pipeline through acquisitions. The deal faced competition from Novo Nordisk but was eventually valued at $10 billion. Anti-obesity drug sales are projected to reach $150 billion by 2035. Pfizer’s promising mid-stage candidate, MET-097i, showed significant weight loss in trials. Pfizer’s pipeline is strong, with a focus on oncology. The company is addressing revenue challenges through cost-cutting measures and tariff exemptions. Investors may find Pfizer’s stock a buy despite challenges. Pfizer wasn’t among the 10 best stocks identified by Stock Advisor for investors. Prosper Junior Bakiny has positions in Novo Nordisk, and The Motley Fool recommends Pfizer.

Read more at Yahoo Finance: Is Pfizer Stock a Buy After This $10 Billion Acquisition?